Our experienced team members have successfully led multiple drug development programs from discovery to launch during their careers and gained professional experience at renowned global pharmaceutical and management consulting companies.
OUR team
Our experienced team members have successfully lead multple drug development programs from discovery to launch during their careers and gained professional expierence at renowned global pharmaceutical and management consulting companies.
Zalán is a Harvard-trained scientist, ex-Mckinsey consultant with extensive experience in the pharma and biotech industry. He is passionate about and experienced in topics where both scientific/medical expertise and management/business excellence are essential to drive maximum impact. He is a life-science focused leader with the ability to recruit, train, and manage high-performing teams demonstrated by 10+ years of leadership in academic and business settings.
Márton Megyeri
PhD, MBA
VP of Platform Development and Scientific Operations
Márton is a Weizmann Institute-trained scientist with a primary degree in bioengineering and a PhD in structural biochemistry. He has 15+ years of academic track record and 10+ years of industrial biotechnology R&D experience with Chemistry, Manufacturing, and Controls (CMC) and Regulatory expertise. He possesses hands-on experience in biologics drug substance and drug product development, along with supporting analytics. Márton has participated in several BPD Type 2 meetings with the FDA and has driven successful IND submissions.
Tamás Kitka
PhD
Managing Director - CREATe Therapeutics
He is a pharmaceutical R&D expert and holds a PhD in Neurobiology. He has 10+ years of experience in the pharmaceutical industry in various positions: researcher/developer, project manager, research team leader, and business development manager. His experience embraces the full non-clinical R&D process in various types of projects (small molecules, biologics, etc.). He participated several projects in either research or development phase that have later been tested in clinical trials.
Tamás Csikai
Chief Financial and Operating Officer
Tamás holds a degree in finance and accounting from the Corvinus University of Budapest and has 10+ years of finance, strategy and operations experience. He started his career at KBC Group as a corporate finance analyst. Later he was a management consultant at McKinsey and Company. Recently, he was a subsidiary finance and operations director at OTP Group. He has previously laid the strategy and successfully built a new venture at OTP Group from scratch via a mix of organic and inorganic (M&A) activities.
Sándor Farkas
MD, PhD
Director of Research and Intellectual Property
Sándor is a non-clinical pharmacologist and drug development scientist, with over 33 years of experience in the pharma Industry. He worked as a research scientist at the University of Tokyo, Japan. His special areas of expertise include all phases of early drug development from target identification to non-clinical support of clinical development. He provided training and education in the discipline of pharmaceutical medicine. Author of 39 scientific publications and inventor of 23 patent applications involving 6 drug candidates that reached clinical development.
Zoltán Urbányi
PhD
Director of Biologics Development
Zoltán is a seasoned life science leader with 35+ years of experience in pharmaceutical R&D including 15+ years in the development of biologics at Gedeon Richter. His career encompasses extensive experience in drug research, management, and project leadership. He has a special expertise in the analytics and characterization of biopharmaceuticals, and he is experienced in the management of the whole preclinical R&D process as well. He participated in several R&D projects including ones with assets that are currently marketed or in clinical phase.
Zalán Péterfi
MD, PhD
Chairman of the Board, Managing Director
Zalán is a Harvard-trained scientist, ex-Mckinsey consultant with extensive experience in the pharma and biotech industry. He is passionate about and experienced in topics where both scientific/medical expertise and management/business excellence are essential to drive maximum impact. He is a life-science focused leader with the ability to recruit, train, and manage high-performing teams demonstrated by 10+ years of leadership in academic and business settings.
Márton Megyeri
PhD, MBA
VP of Scientific Operations
Márton is a Weizmann Institute-trained scientist with a primary degree in bioengineering and a PhD in structural biochemistry. He has 15+ years of academic track record and 10+ years of industrial biotechnology R&D experience with Chemistry, Manufacturing, and Controls (CMC) and Regulatory expertise. He possesses hands-on experience in biologics drug substance and drug product development, along with supporting analytics. Márton has participated in several BPD Type 2 meetings with the FDA and has driven successful IND submissions.
Tamás Kitka
PhD
Director of Portfolio and Innovation
He is a pharmaceutical R&D expert and holds a PhD in Neurobiology. He has 10+ years of experience in the pharmaceutical industry in various positions: researcher/developer, project manager, research team leader, and business development manager. His experience embraces the full non-clinical R&D process in various types of projects (small molecules, biologics, etc.). He participated several projects in either research or development phase that have later been tested in clinical trials.
Tamás Csikai
Chief Financial and Operating Officer
Tamás holds a degree in finance and accounting from the Corvinus University of Budapest and has 10+ years of finance, strategy and operations experience. He started his career at KBC Group as a corporate finance analyst. Later he was a management consultant at McKinsey and Company. Recently, he was a subsidiary finance and operations director at OTP Group. He has previously laid the strategy and successfully built a new venture at OTP Group from scratch via a mix of organic and inorganic (M&A) activities.
Sándor Farkas
MD, PhD
Director of Research and Intellectual Property
Sándor is a non-clinical pharmacologist and drug development scientist, with over 33 years of experience in the pharma Industry. He worked as a research scientist at the University of Tokyo, Japan. His special areas of expertise include all phases of early drug development from target identification to non-clinical support of clinical development. He provided training and education in the discipline of pharmaceutical medicine. Author of 39 scientific publications and inventor of 23 patent applications involving 6 drug candidates that reached clinical development.
Zoltán Urbányi
PhD
Director of Biologics Development
Zoltán is a seasoned life science leader with 35+ years of experience in pharmaceutical R&D including 15+ years in the development of biologics at Gedeon Richter. His career encompasses extensive experience in drug research, management, and project leadership. He has a special expertise in the analytics and characterization of biopharmaceuticals, and he is experienced in the management of the whole preclinical R&D process as well. He participated in several R&D projects including ones with assets that are currently marketed or in clinical phase.
Péter Kovács
PhD
VP of Medical & Scientific Affairs
Peter is neurobiologist PhD academy-industry expert with hands-on experience in every facet of drug research and commercialization, from innovative concepts to product launches. He led research teams focused on CNS-targeted small molecule preclinical drug discovery, identifying new drug targets that successfully advanced to the clinical phase. He also possesses significant clinical development, medico-marketing and regulatory experience across various therapeutic areas. He is passionate about bridging the gap between research and real-world impact.
Zalán Péterfi
MD, PhD
Chairman of the Board, Managing Director
Zalán is a Harvard-trained scientist, ex-Mckinsey consultant with extensive experience in the pharma and biotech industry. He is passionate about and experienced in topics where both scientific/medical expertise and management/business excellence are essential to drive maximum impact. He is a life-science focused leader with the ability to recruit, train, and manage high-performing teams demonstrated by 10+ years of leadership in academic and business settings.
Péter Puskás
MD, MBA
Member of the Board
Peter is the co-founder and CEO of Sycamore Capital Partners; a Budapest based Private Equity company and leads Vascular Group as CEO. Before assuming this position, he had gained extensive pharma industry experience at McKinsey and Company where he worked for 10+ years and was the CEE regional co-leader of McKinsey’s healthcare and pharmaceutical practice. Peter has a degree in Medicine (MD), a Master’s Degree in Economics from Corvinus University, and also obtained his MBA degree at INSEAD, Singapore.
János Kővágó
Member of the Board
János has 25 years of background as an investment banker and as a senior consultant in a number of public and private corporate finance transactions (listings and sales advisory). He has extensive experience in the following industries: automation, software, MedTech, 'BPO/outsourced services. He closed several international financial transactions in these industries. Over the past decade, he has worked for major international companies such as Daiwa Securities, ING Barings, Nomura Securities, Citibank, Egis Pharmaceuticals Zrt., and Grant Thornton before joining Széchenyi Funds as an Investment Director.
Zalán Péterfi
MD, PhD
Chairman of the Board, Managing Director
Zalán is a Harvard-trained scientist, ex-Mckinsey consultant with extensive experience in the pharma and biotech industry. He is passionate about and experienced in topics where both scientific/medical expertise and management/business excellence are essential to drive maximum impact. He is a life-science focused leader with the ability to recruit, train, and manage high-performing teams demonstrated by 10+ years of leadership in academic and business settings.
Péter Puskás
MD, MBA
Member of the Board
Peter is the co-founder and CEO of Sycamore Capital Partners; a Budapest based Private Equity company and leads Vascular Group as CEO. Before assuming this position, he had gained extensive pharma industry experience at McKinsey and Company where he worked for 10+ years and was the CEE regional co-leader of McKinsey’s healthcare and pharmaceutical practice. Peter has a degree in Medicine (MD), a Master’s Degree in Economics from Corvinus University, and also obtained his MBA degree at INSEAD, Singapore.
János Kővágó
Member of the Board
János has 25 years of background as an investment banker and as a senior consultant in a number of public and private corporate finance transactions (listings and sales advisory). He has extensive experience in the following industries: automation, software, MedTech, 'BPO/outsourced services. He closed several international financial transactions in these industries. Over the past decade, he has worked for major international companies such as Daiwa Securities, ING Barings, Nomura Securities, Citibank, Egis Pharmaceuticals Zrt., and Grant Thornton before joining Széchenyi Funds as an Investment Director.
Ádám Jenőfalvi
Scientist Trainee
Ágnes Golarits
Scientist Trainee
Ambrus Gordos
PharmD
Scientist Trainee, Bioinformatician
Anna Hajdara
Junior Scientist, Junior Project Manager
Anna Hollósi
PhD
Scientific Project Manager
Attila Brunyánszki
PhD
Research Operations Manager, Head of Cell Laboratory
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
